Cormorant Asset Management, LP - AUTOLUS THERAPEUTICS PLC ownership

AUTOLUS THERAPEUTICS PLC's ticker is AUTL and the CUSIP is 05280R100. A total of 64 filers reported holding AUTOLUS THERAPEUTICS PLC in Q1 2023. The put-call ratio across all filers is 0.27 and the average weighting 1.1%.

Quarter-by-quarter ownership
Cormorant Asset Management, LP ownership history of AUTOLUS THERAPEUTICS PLC
ValueSharesWeighting
Q3 2023$913,749
-2.1%
392,1670.0%0.05%
+1.9%
Q2 2023$933,357
+129173.8%
392,1670.0%0.05%
+8.3%
Q1 2023$722
-3.1%
392,1670.0%0.05%
-4.0%
Q4 2022$745
-99.9%
392,1670.0%0.05%
-15.3%
Q3 2022$839,000
-24.4%
392,1670.0%0.06%
-29.8%
Q2 2022$1,110,000
-32.1%
392,1670.0%0.08%
-33.3%
Q1 2022$1,635,000
-19.7%
392,1670.0%0.13%
+4.1%
Q4 2021$2,035,000
-20.8%
392,1670.0%0.12%
+16.3%
Q3 2021$2,569,000
-1.3%
392,1670.0%0.10%
+18.2%
Q2 2021$2,604,000
+7.6%
392,167
-7.1%
0.09%
+63.0%
Q1 2021$2,419,000
-35.9%
422,1670.0%0.05%
-40.0%
Q4 2020$3,774,000
-23.2%
422,1670.0%0.09%
-52.4%
Q3 2020$4,914,000
-36.1%
422,167
-12.0%
0.19%
-35.7%
Q2 2020$7,694,000
+167.6%
479,9880.0%0.29%
+119.4%
Q1 2020$2,875,000
-54.6%
479,9880.0%0.13%
-47.0%
Q4 2019$6,336,000
+6.3%
479,9880.0%0.25%
-30.3%
Q3 2019$5,961,000
-47.1%
479,988
-31.4%
0.36%
-43.9%
Q2 2019$11,270,000
-57.9%
700,000
-17.6%
0.65%
-64.2%
Q1 2019$26,750,000
-34.2%
850,000
-35.9%
1.81%
-31.6%
Q3 2018$40,673,000
-0.5%
1,326,136
-13.1%
2.64%
-12.6%
Q2 2018$40,870,0001,525,5873.02%
Other shareholders
AUTOLUS THERAPEUTICS PLC shareholders Q1 2023
NameSharesValueWeighting ↓
FRAZIER MANAGEMENT LLC 3,530,657$23,126,0001.85%
TFG Asset Management GP Ltd 2,500,000$16,375,0001.00%
Nantahala Capital Management 2,936,791$19,236,0000.61%
MYDA Advisors LLC 171,953$1,126,0000.32%
SABBY MANAGEMENT, LLC 300,000$1,965,0000.27%
Regency Capital Management Inc.\DE 57,000$373,0000.26%
Ikarian Capital, LLC 544,819$3,568,0000.25%
Eversept Partners, LP 398,074$2,607,3850.18%
Henry James International Management Inc. 54,047$354,0000.11%
Alphabet Inc. 698,262$4,574,0000.11%
View complete list of AUTOLUS THERAPEUTICS PLC shareholders